Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

hodgkin's disease
malt
systemic therapy
b-cell lymphoma
refractory follicular lymphoma
  • 0 views
  • 16 Feb, 2024
  • 36 locations
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Adults who have been diagnosed with B-cell non-Hodgkin lymphoma (NHL) that has relapsed or no longer responds to chemotherapy (relapsed or refractory) may be eligible to participate in this study.

hodgkin's disease
b-cell lymphoma
graft versus host disease
lymphoma
flow cytometry
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

This is a multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of ATG-019, a dual inhibitor of PAK4 and NAMPT, alone or co-administered with starting dose of 500 mg niacin ER in patients with advanced solid tumors or non-Hodgkin's lymphoma

  • 0 views
  • 16 Feb, 2024
  • 5 locations
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for 35% of lymphoma. Chimeric antigen receptor T cell (CAR-T) therapy is a new method to treat DLBCL. KTE-C19, published in the New England Medical Journal in December 2017, was used to treat relapsed and refractory B-cell lymphoma.

hodgkin's disease
b-cell lymphoma
antibody therapy
lymphoma
flow cytometry
  • 0 views
  • 05 Aug, 2020
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

hodgkin's disease
lymphocytic leukemia
chronic lymphocytic leukemia
lymphoma
lymphoid leukemia
  • 0 views
  • 16 Feb, 2024
  • 6 locations
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Hodgkin Lymphoma

This trial studies how well a mind-body intervention works in improving overall quality of life in adolescents and young adults with Hodgkin lymphoma. A meditation based mind-body intervention may help lower distress, depressive symptoms, and anxiety in adolescents and young adults coping with Hodgkin lymphoma.

mind-body medicine
adult hodgkin lymphoma
depressive symptoms
anxiety
lymphoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

hodgkin's disease
oral contraceptives
bendamustine
brentuximab vedotin
peripheral t-cell lymphoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

hodgkin's disease
lymphoma
neuropathy
cancer therapy
cancer
  • 0 views
  • 04 Dec, 2020
  • 5 locations
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

This is a phase I/II, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult with R/R Non-Hodgkins Lymphoma in China.

hodgkin's disease
targeted therapy
lymphoma
non-hodgkin lymphoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

high-dose chemotherapy
analgesia
multiple myeloma
lymphoma
opioid
  • 0 views
  • 16 Feb, 2024
  • 2 locations